Beam Therapeutics Inc.
BEAM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $2 |
| - Cash | $0 | $0 | $1 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 14.6% | 13.3% | -75.2% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,031.9% | -1,102% | -1,222.8% | -237.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,105.1% | -1,353.8% | -1,522.9% | -314.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,162.4% | -1,208.3% | -1,462.8% | -300.5% |
| EPS Diluted | -1.1 | -1 | -1.24 | -1.09 |
| % Growth | -10% | 19.4% | -13.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |